{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:13:36Z","timestamp":1789737216599,"version":"4.0.1"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9,1]]},"DOI":"10.1164\/rccm.201206-1137ed","type":"journal-article","created":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T16:47:15Z","timestamp":1346518035000},"page":"396-397","source":"Crossref","is-referenced-by-count":26,"title":["The 6-Minute Walk Test in Pulmonary Arterial Hypertension: How Far Is Enough?"],"prefix":"10.1093","volume":"186","author":[{"given":"Lewis J.","family":"Rubin","sequence":"first","affiliation":[{"name":"University of California, San Diego School of Medicine, La Jolla California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,9,1]]},"reference":[{"key":"2026032101021155400_bib1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"2026032101021155400_bib2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"2026032101021155400_bib3","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"key":"2026032101021155400_bib4","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101021155400_bib5","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"2026032101021155400_bib6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"2026032101021155400_bib7","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026032101021155400_bib8","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"key":"2026032101021155400_bib9","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201203-0480OC","article-title":"The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension","volume":"186","author":"Mathai","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101021155400_bib10","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.healun.2010.11.009","article-title":"Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension","volume":"30","author":"Barst","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"2026032101021155400_bib11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/CIRCULATIONAHA.112.105890","article-title":"Validation of 6-minute-walk distance as a surrogate end point in pulmonary arterial hypertension trials","volume":"126","author":"Gabler","year":"2012","journal-title":"Circulation"},{"key":"2026032101021155400_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"key":"2026032101021155400_bib13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"key":"2026032101021155400_bib14","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026032101021155400_bib15","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","article-title":"ACCF\/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026032101021155400_bib16","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1183\/09031936.05.00075305","article-title":"Goal-oriented treatment and combination therapy for pulmonary arterial hypertension","volume":"26","author":"Hoeper","year":"2005","journal-title":"Eur Respir J"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/186\/5\/396\/67291972\/ajrccm_186_5_396.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/186\/5\/396\/67291972\/ajrccm_186_5_396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:02:19Z","timestamp":1774069339000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/186\/5\/396\/8507713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,1]]},"references-count":16,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,9,1]]},"published-print":{"date-parts":[[2012,9,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201206-1137ed","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,9]]},"published":{"date-parts":[[2012,9,1]]}}}